Search Results - "Chiou, Chang‐Ta"

Malignant development in patients with oral potentially malignant disorders detected through nationwide screening: Outcomes of 5‐year follow‐up at a single hospital by Chiang, Wei‐Fan, Liu, Shyun‐Yeu, Lin, Jen‐Fen, Chiu, Sheng‐Fu, Gou, Shin‐Bin, Chiou, Chang‐Ta, Chang, Chi‐Hua

“…Background Although survival rate and quality of life are improved if patients with oral carcinoma can be detected early, however, such lesions are usually…”
Get full text

Risk analysis of malignant potential of oral verrucous hyperplasia: A follow‐up study of 269 patients and copy number variation analysis by Wu, Ming‐Heng, Luo, Ji‐Dung, Wang, Wen‐Chang, Chang, Tzu‐Hao, Hwang, Wei‐Lun, Lee, Kuen‐Haur, Liu, Shyun‐Yeu, Yang, Jung‐Wu, Chiou, Chang‐Ta, Chang, Chi‐Hua, Chiang, Wei‐Fan

“…Background Oral verrucous hyperplasia is commonly observed in the oral cavity of betel quid chewers and is a potential malignant disorder. However, the…”
Get full text

Surgical outcomes and prognostic factors of oral cancer associated with betel quid chewing and tobacco smoking in Taiwan by Liu, Shyun-Yeu, Lu, Chin-Li, Chiou, Chang-Ta, Yen, Ching-Yu, Liaw, Gwo-An, Chen, Yi-Chun, Liu, Yu-Chi, Chiang, Wei-Fan

“…Summary Oral squamous cell carcinoma (OSCC) is one of the most common cancers in geographic regions where betel quid (BQ) chewing is prevalent; OSCC is an…”
Get full text

Outcome of Treatment with Total Main Tumor Resection and Supraomohyoid Neck Dissection in Oral Squamous Cell Carcinoma by Gwo-An Liaw, Ching-Yu Yen, Wei-Fan Chiang, Chin-Hai Lee, Cheng Yang, Chang-Ta Chiou, Shyun-Yeu Liu

“…Supraomohyoid neck dissection (SOHND) is commonly used to treat oral squa-mous cell carcinoma (OSCC) patients with clinical N0 or selected N1 status. The…”
Get full text

Outcome of treatment with total main tumor resection and supraomohyoid neck dissection in oral squamous cell carcinoma by Liaw, Gwo-An, Yen, Ching-Yu, Chiang, Wei-Fan, Lee, Chin-Hai, Yang, Cheng, Chiou, Chang-Ta, Liu, Shyun-Yeu

“…Supraomohyoid neck dissection (SOHND) is commonly used to treat oral squamous cell carcinoma (OSCC) patients with clinical N0 or selected N1 status. The…”
Get more information